Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTA-C1-INH single-dose pharmacokinetic study in hereditary angioedema
2019-001693-28Phase 2Completed
- Sponsor
- Octapharma
- Start
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of C1 inhibitor, human in hereditary angioedema (HAE), sponsored by Octapharma. Primary endpoint: Pharmacokinetic parameters of OCTA-C1-INH measured as C1-INH activity. Started Sep 2019; status: completed.
02
Drugs
C1 inhibitor, human
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2019-001693-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001693-28.